Skip to Main Content
Contribute Try STAT+ Today

SAN FRANCISCO — Verily was one of the most-talked-about debutants at this year’s J.P. Morgan ball. For the first time in its five-year history, the Alphabet life sciences spinout presented to some of the 9,000 health care executives and investors who descended upon Union Square, and Verily’s mercurial CEO, Andy Conrad, faced pressure both to impress and entertain.

The conference room was standing room only on Monday as an enthusiastic Conrad, clad in the Silicon Valley uniform of pullover sweater and open-collar shirt, described some of the company’s numerous projects, teasing details that he said he’d never before shared with the public.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.